Texas A&M Nasal Spray Reverses Brain Aging
Analysis based on 7 articles · First reported Apr 14, 2026 · Last updated Apr 19, 2026
This breakthrough by Texas A&M University could significantly impact the biotechnology and pharmaceutical industries by offering a novel, non-invasive treatment for neurodegenerative diseases. The potential to reverse brain aging and reduce dementia cases, particularly in the United States, presents a substantial new market opportunity for related therapies and investments.
Researchers at Texas A&M University, led by Ashok Shetty, Madhu Leelavathi Narayana, and Maheedhar Kodali, have developed a nasal spray that dramatically reduces brain inflammation and improves memory in aging models. This therapy, detailed in the Journal of Extracellular Vesicles, uses extracellular vesicles (EVs) carrying microRNAs to directly target and suppress inflammatory pathways in the brain, while also recharging neuronal mitochondria. The treatment showed rapid results, appearing within weeks and lasting for months, and was effective across both genders. The team has filed a U.S. patent for the therapy, which was backed by the United States — National Institutes of Health. This development could revolutionize treatments for neurodegenerative disorders like Alzheimer's and dementia, addressing the projected doubling of dementia cases in the United States by 2060.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard